Takahashi wins 2026 prize for iPS cell Parkinson’s therapy

Jun Takahashi, MD, PhD, has received the 2026 Ogawa-Yamanaka Stem Cell Prize for his pioneering work translating induced pluripotent stem cell biology into a regenerative therapy for Parkinson’s disease. Gladstone Institutes, which announced the award, said Takahashi’s program culminated in the first clinical approval anywhere in the world for an iPS cell-derived therapeutic product. His team began the first clinical trial of an iPS cell-derived treatment for Parkinson’s disease in 2018, and its work ultimately contributed to conditional, time-limited regulatory approval in Japan in 2026. The announcement describes a research and development pathway that moved from induced pluripotent stem cell biology through laboratory investigation, human clinical testing and regulatory review.

The prize was established in 2015 through a gift from the Hiro and Betty Ogawa family and is supported by Gladstone Institutes in partnership with Cell Press. It recognizes scientists conducting original translational research that has advanced cellular reprogramming for regenerative medicine, and it also bears the name of Shinya Yamanaka, MD, PhD, whose discovery of iPS cells earned him the Nobel Prize in 2012. An independent committee of international stem cell experts selected Takahashi from a competitive pool of nominees. As the 2026 recipient, he will receive an unrestricted prize of $150,000. Gladstone will host the award ceremony on Nov. 19 in San Francisco, when Takahashi is scheduled to give a scientific lecture and receive the award.

At the center of Takahashi’s recognized work is a therapeutic platform based on induced pluripotent stem cells, commonly called iPS cells. These cells are produced by reprogramming ordinary adult cells, including skin or blood cells, so that they act like embryonic stem cells. In this immature and flexible state, they can be developed into many human cell types, including brain, heart and liver cells. Takahashi’s research focused on stem cell-based treatments for neurological disorders, particularly Parkinson’s disease. Beyond that disease, the announcement says he helped establish a practical framework for moving iPS cell-derived therapies toward clinical use for other conditions in need of better treatment options.

Takahashi’s team conducted what the award announcement calls the world’s first clinical trial of an iPS cell-derived therapy for Parkinson’s disease from 2018 to 2023. The announcement states that the work ultimately contributed to the first regulatory approval of an iPS cell-derived therapeutic product. Japan granted that approval in 2026 on a conditional and time-limited basis. This regulatory milestone should not be conflated with a finding about the treatment’s long-term effectiveness: the announcement does not present a detailed analysis of symptom improvement, durability, comparative benefit or patient outcomes. What it reports is the approval of a product developed through an iPS cell-based approach for Parkinson’s disease.

Takahashi’s route into the field joined clinical medicine with laboratory research and scientific administration. He received his medical degree from Kyoto University and began his career in neurosurgery at Kyoto University Hospital. He later earned his doctorate from the Kyoto University Graduate School of Medicine and conducted postdoctoral research on neural stem cells in the laboratory of Fred Gage at the Salk Institute. He joined Kyoto University’s Center for iPS Cell Research and Application, or CiRA, as a founding member in 2010 and became a professor there in 2012. He served as CiRA’s director from 2022 to 2026 and is identified in the announcement as a former director and professor at the center.

Deepak Srivastava, MD, president of Gladstone, chair of the prize’s selection committee and director of the Roddenberry Stem Cell Center, praised the progression of Takahashi’s work from an idea in the laboratory through scientific and clinical milestones. In the announcement, Srivastava said Takahashi had carried an idea from the lab through the many scientific and clinical milestones required to make an impact on patients. He described the work as demonstrating the extraordinary potential of iPS cell technology as a foundation for new treatments. His comments recognized the translational achievement represented by the development and regulatory approval of an iPS cell-derived product for Parkinson’s disease.

Takahashi said the recognition was a great honor, particularly because his work had been built on Shinya Yamanaka’s discovery of iPS cell technology. He expressed the hope that the experience of developing an iPS cell-based therapy for Parkinson’s disease would open a path for regenerative medicine to reach more patients with neurological and other diseases. That statement expresses a broader aspiration for future treatment development; it does not indicate that additional iPS cell therapies have already been approved. The 2026 award nevertheless marks a concrete milestone in translational regenerative medicine, according to Gladstone: a Parkinson’s disease product developed through the iPS cell platform has reached clinical approval.

The award also has a direct connection to Yamanaka, who is a Gladstone senior investigator and director emeritus of CiRA. Yamanaka’s discovery of iPS cell technology opened possibilities for innovative medicines and biological discoveries, while the Ogawa-Yamanaka prize has developed its own record of recognizing work in reprogrammed cells and regenerative medicine. Previous recipients include Masayo Takahashi in 2015, Douglas Melton in 2016, Lorenz Studer in 2017, Marius Wernig in 2018, Gordon Keller in 2019, Juan Carlos Izpisua Belmonte in 2022, Magdalena Zernicka-Goetz in 2023, Rusty Gage in 2024 and Rudolf Jaenisch in 2025.

The 2026 selection committee consisted of George Daley, MD, PhD, dean of Harvard Medical School; Hideyuki Okano, MD, PhD, dean of the School of Medicine at Keio University; Srivastava; Studer; Fiona Watt, FRS, FMedSci, director of the Centre for Stem Cells and Regenerative Medicine at King’s College London; and Yamanaka. Their selection recognized Takahashi’s original translational research, particularly the work that connected cellular reprogramming with a clinical trial and the first regulatory approval of an iPS cell-derived therapeutic product. His honors also include the Michael J. Fox Foundation for Parkinson’s Research Cell Replacement Therapy for Parkinson’s Disease Award and the Japanese Society for Regenerative Medicine Award.

Beyond the regulatory milestone, Takahashi’s career illustrates how scientific, clinical and organizational efforts can converge around reprogrammed cells. He moved from neurosurgical training and neural stem cell research into the development of iPS cell-based therapies, then helped direct a major interdisciplinary center as it pursued clinical translation. His team applied the technology to a neurodegenerative disease and produced an iPS cell-derived therapeutic product that received clinical approval. The announcement presents this as the first such approval worldwide, making the prize recognition grounded in an achieved regulatory milestone rather than a forecast or a general promise about regenerative medicine. The ceremony in San Francisco will formally honor a scientist whose work helped establish a route from iPS cell discovery to a clinical pathway for Parkinson’s disease.

Subject of Research: Recognition of Jun Takahashi for translating iPS cell technology into an approved regenerative therapy for Parkinson’s disease.

Article Title: The 2026 Ogawa-Yamanaka Stem Cell Prize awarded to Jun Takahashi

Article References: The 2026 Ogawa-Yamanaka Stem Cell Prize awarded to Jun Takahashi. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Jun Takahashi, Ogawa-Yamanaka Prize, iPS cells, Parkinson’s disease, cellular reprogramming, regenerative medicine, clinical translation, Kyoto University, CiRA, stem cell therapy, Ogawa-Yamanaka, Stem